Trader consensus on Polymarket heavily favors no acquisition of Anthropic before 2027, with "No" implying a 92% probability, driven by the company's aggressive expansion as an acquirer rather than a target. In early April 2026, Anthropic completed a $400 million all-stock purchase of stealth biotech AI startup Coefficient Bio, following its February acquisition of computer-use specialist Vercept and December 2025 buy of Bun—moves bolstering Claude model's capabilities in drug discovery and agentic AI without ceding control. Reports of IPO preparations via Wilson Sonsini and rejected multibillion-dollar offers, alongside tripled revenue to a $30 billion run-rate, underscore CEO Dario Amodei's commitment to independence amid U.S. defense contract disputes. While economic pressures or a transformative big tech bid from investors like Amazon or Google could shift dynamics, traders see standalone growth via upcoming Claude Opus 4.7 enhancements and London expansion as the dominant path.
Polymarket verilerine atıfta bulunan deneysel AI tarafından oluşturulmuş özet. Bu bir işlem tavsiyesi değildir ve bu piyasanın nasıl çözümlendiğinde hiçbir rolü yoktur. · GüncellendiEvet
$14,758 Hac.
$14,758 Hac.
31 Ara 2026
Evet
$14,758 Hac.
$14,758 Hac.
31 Ara 2026
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Trader consensus on Polymarket heavily favors no acquisition of Anthropic before 2027, with "No" implying a 92% probability, driven by the company's aggressive expansion as an acquirer rather than a target. In early April 2026, Anthropic completed a $400 million all-stock purchase of stealth biotech AI startup Coefficient Bio, following its February acquisition of computer-use specialist Vercept and December 2025 buy of Bun—moves bolstering Claude model's capabilities in drug discovery and agentic AI without ceding control. Reports of IPO preparations via Wilson Sonsini and rejected multibillion-dollar offers, alongside tripled revenue to a $30 billion run-rate, underscore CEO Dario Amodei's commitment to independence amid U.S. defense contract disputes. While economic pressures or a transformative big tech bid from investors like Amazon or Google could shift dynamics, traders see standalone growth via upcoming Claude Opus 4.7 enhancements and London expansion as the dominant path.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Piyasa Açıldı: Nov 12, 2025, 5:14 PM ET
Hacim
$14,758Bitiş Tarihi
31 Ara 2026Piyasa Açıldı
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.Trader consensus on Polymarket heavily favors no acquisition of Anthropic before 2027, with "No" implying a 92% probability, driven by the company's aggressive expansion as an acquirer rather than a target. In early April 2026, Anthropic completed a $400 million all-stock purchase of stealth biotech AI startup Coefficient Bio, following its February acquisition of computer-use specialist Vercept and December 2025 buy of Bun—moves bolstering Claude model's capabilities in drug discovery and agentic AI without ceding control. Reports of IPO preparations via Wilson Sonsini and rejected multibillion-dollar offers, alongside tripled revenue to a $30 billion run-rate, underscore CEO Dario Amodei's commitment to independence amid U.S. defense contract disputes. While economic pressures or a transformative big tech bid from investors like Amazon or Google could shift dynamics, traders see standalone growth via upcoming Claude Opus 4.7 enhancements and London expansion as the dominant path.
This market will resolve to “Yes” if credible reporting confirms that any entity enters into an agreement to acquire Anthropic by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Mergers where Anthropic is subsumed by another entity will count toward a "Yes" resolution.
An announced agreement between Anthropic and an acquiring entity will qualify for a “Yes” resolution, regardless of whether the acquisition is ultimately completed.
The primary resolution source for this market is official information from Anthropic and/or its leadership, however a consensus of credible reporting will also be used.
Hacim
$14,758Bitiş Tarihi
31 Ara 2026Piyasa Açıldı
Nov 12, 2025, 5:14 PM ETResolver
0x65070BE91...Trader consensus on Polymarket heavily favors no acquisition of Anthropic before 2027, with "No" implying a 92% probability, driven by the company's aggressive expansion as an acquirer rather than a target. In early April 2026, Anthropic completed a $400 million all-stock purchase of stealth biotech AI startup Coefficient Bio, following its February acquisition of computer-use specialist Vercept and December 2025 buy of Bun—moves bolstering Claude model's capabilities in drug discovery and agentic AI without ceding control. Reports of IPO preparations via Wilson Sonsini and rejected multibillion-dollar offers, alongside tripled revenue to a $30 billion run-rate, underscore CEO Dario Amodei's commitment to independence amid U.S. defense contract disputes. While economic pressures or a transformative big tech bid from investors like Amazon or Google could shift dynamics, traders see standalone growth via upcoming Claude Opus 4.7 enhancements and London expansion as the dominant path.
Polymarket verilerine atıfta bulunan deneysel AI tarafından oluşturulmuş özet. Bu bir işlem tavsiyesi değildir ve bu piyasanın nasıl çözümlendiğinde hiçbir rolü yoktur. · Güncellendi
Harici bağlantılara dikkat edin.
Harici bağlantılara dikkat edin.
Sıkça Sorulan Sorular